Other languages Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-30 EDT			5-day change	1st Jan Change
1,468 ^JPY	+0.69%		+0.07%	+3.31%

04-18	Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	MT
04-17	Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	04-16
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	04-14
Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC	04-03
Sosei Shareholders Greenlight Name Change, Top Management Appointments	03-28
Sosei Group Corporation Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	03-20
Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease	03-20
Idorsia perçoit 350 millions de dollars pour les sélatogreé et cénérimod	03-18
Sosei Group, Boehringer Ingelheim Enter Into License Deal for Schizophrenia Symptoms	03-12
Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-In-Class Treatments Targeting All Symptoms of Schizophrenia	03-11
Boehringer Ingelheim and Sosei Group Corporation Enter Exclusive Option-To- License Agreement	03-11
Japanese Shares Close Lower But Hit Fresh 52-Week High on US Rate Cut Assurance	03-07
Sosei Group to Get $2.5 Million Milestone Payment from Formosa Pharmaceuticals	03-07
Sosei Group Corporation to Receive $2.5 Million Payment from Formosa Pharmaceuticals	03-06
Idorsia cède encore des programmes en échange de financements	02-28
Drugmakers deepen efforts to tap into booming market for obesity drugs	02-27
Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer	01-05
Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea	12-07
Sosei Partner to Conduct Early Stage Trials of Neurological Disease Drug Candidates	12-06
Roche enters obesity drugs race with $2.7 bln Carmot deal	12-04
Roche enters obesity drugs race with $2.7 bln Carmot deal	12-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Other languages

Filters